A sensitive enzyme immunoassay for human basic fibroblast growth factor

doi:10.1016/S0006-291X(05)81224-0

Biochemical and Biophysical Research Communications

Volume 175, Issue 1, 28 February 1991, Pages 229-235

https://doi.org/10.1016/S0006-291X(05)81224-0 Get rights and content

Summary

A sensitive sandwich enzyme immunoassay for human basic fibroblast growth factor (HbFGF) was developed employing three monoclonal antibodies (MAb3H3, MAb98 and MAb52). The Fab' fragment of MAb3H3 which inhibits HbFGF biological activity was conjugated to horseradish peroxidase. A mixture of MAb52 and MAb98 was used in the solid phase. Neiter human acidic fibroblast growth factor, hst-1/KS3 product nor acid denatured HbFGF was cross-reactive in this assay system. The detection limit of this assay system was 1 pg/well. Using this assay, some tumor cell lines were revealed to produce a higher level of bFGF than a normal one. Serum samples from normal volunteers were also assayed, and immuno-reactive HbFGF could be detected in 16 out of 57 samples at range 30∼206 pg/ml.

References (19)

GospodarowiczD.
Methods in Enzymol.
(1987)
IwaneM. et al.
Biochem. Biophys. Res. Commun.
(1987)
PavluB. et al.
J. Chromato.
(1986)
KurokawaT. et al.
FEBS Lett.
(1987)
SakaguchiM. et al.
FEBS Lett.
(1988)
LobbR. et al.
J. Biol. Chem
(1986)
BurgessW.H. et al.
Annu. Rev. Biochem.
(1989)
SenoM. et al.
Hybridoma
(1989)
SatoY. et al.
Mol. Endcrinol.
(1989)

There are more references available in the full text version of this article.

Cited by (76)

Serum Protein Expression Predicts Recurrence in Patients With Early-Stage Lung Cancer After Resection
2006, Annals of Thoracic Surgery
Patients with early stage nonsmall-cell lung cancer who have undergone complete resection have a recurrence rate of approximately 50%, predominately due to the development of systemic metastases. This study is a prospective analysis of the expression of seven serum protein markers of invasion and metastasis, collected preoperatively (baseline) and serially after resection, to determine the relationship between marker expression and recurrence.
Serum was collected from 196 patients with clinical stage I nonsmall-cell lung cancer who underwent resection over a 5-year period (1996 to 2000). Samples were drawn before resection and 1, 4, 6, 12, 18, and 24 months postoperatively. All patients were followed for at least 24 months or until death. Serum protein levels of vascular endothelial growth factor, hepatocyte growth factor), E-selectin, CD44, basic fibroblast growth factor, urokinase plasminogen activator, and urokinase plasminogen activator receptor were determined using enzyme-linked immunosorbent assay.
To date, 73 patients (37%) have demonstrated recurrence. Baseline levels of only 1 marker (CD44) correlated with pathologic stage (p = 0.02). Analysis of the serial samples demonstrated that recurrence was predicted (before clinical or radiographic determination) by decreasing levels of E-selectin (p = 0.002), increasing levels of CD44 (p = 0.001), and increasing levels of urokinase plasminogen activator receptor (p = 0.03).
This study demonstrates the potential to predict recurrence after resection in patients with early-stage nonsmall-cell lung cancer using a panel of serum protein markers. Early identification of patients with recurrence may improve the efficacy of systemic therapy.
Fibroblast growth factors and their receptors in transitional cell carcinoma
2003, Journal of Urology
The recent identification in transitional cell carcinoma of mutations in a fibroblast growth factor (FGF) receptor, namely FGF receptor-3, has provoked great interest in the potential usefulness of FGF receptors and their ligands as molecular markers and as targets for bladder cancer therapy. We examined these possibilities in light of the published literature.
We reviewed the world literature on FGFs and their receptors from 1966 to January 2002 using PubMed.
The recent identification in transitional cell carcinoma of a high frequency of mutations in FGF receptor-3 predicted to activate kinase activity of the receptor indicate a likely role as an oncogene in the urothelium. The finding of FGF receptor-3 mutations only rarely in other tumor types to date indicates surprising urothelial specificity that requires tissue specific approaches for evaluation and exploitation. In contrast, FGF receptor-2 expression is down-regulated in bladder tumors, suggesting a possible tumor suppressor role. Information is available on the expression of FGF receptors-1 and 2 in normal bladder and urine, and in bladder tumors. These angiogenic factors represent potential urine markers of bladder neoplasia, although as single markers they lack sufficient sensitivity and specificity. Some interesting insights into the potential role of these factors have come from studies using in vitro model systems. However, there is little information on the numerous other members of this family of growth factors in the bladder and, therefore, much scope for future studies.
It is clear that the FGFs and their receptors have important roles in the development of transitional cell carcinoma. Undoubtedly it will be a focus for much future research. It can be anticipated that members of these protein families would represent useful clinical markers and potential targets for bladder cancer therapy.
Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line
1998, Cancer Letters
To clarify the role of basic fibroblast growth factor (FGF-2) in the drug resistance of bladder cancer, we transfected the FGF-2 gene into HT1376, an FGF-2 negative human bladder cancer cell line. The FGF-2-transfected cell lines exhibited three- to four-fold higher resistant potential to cisplatin than the vector-only transfected control cell lines in vitro. When cisplatin was injected intraperitoneally after s.c. implantation of HT1376 sublines into nude mice, FGF-2 transfectants formed tumors about twice as large as did controls. In contrast, there was no significant difference in either cell proliferation in vitro or tumor growth in vivo among these cell lines without cisplatin treatment. Furthermore, DNA degradation following cisplatin treatment was markedly suppressed in FGF-2 transfectants compared to control cells. These results suggest that the expression of the FGF-2 gene plays an important role in the acquisition of the cisplatin-resistant phenotype of bladder cancer, probably through the protection against cisplatin-induced apoptosis.
A mutein of human basic fibroblast growth factor TGP-580 accelerates colonic ulcer healing by stimulating angiogenesis in the ulcer bed in rats
2015, Journal of Physiology and Pharmacology
Engineering strategies to recapitulate the tumor microenvironment
2015, Cells, Forces, and the Microenvironment
Predictive markers in bladder cancer: Do we have molecular markers ready for clinical use?
2014, Critical Reviews in Clinical Laboratory Sciences

View all citing articles on Scopus

View full text

A sensitive enzyme immunoassay for human basic fibroblast growth factor

Summary

Methods in Enzymol.

Biochem. Biophys. Res. Commun.

J. Chromato.

FEBS Lett.

FEBS Lett.

J. Biol. Chem

Annu. Rev. Biochem.

Hybridoma

Mol. Endcrinol.